Overview
Optimizing Ischemic Outcomes in ACS: Formulating Antiplatelet Therapies Across Complex Clinical Scenarios
An Evening Program at C3
Registration is closed for this activity.
Join us for this featured symposium at the C³ 2018 Conference, where expert faculty will discuss:
• Improving individualized dual antiplatelet regimens in complex patients
• Performing genetic testing to guide DAPT
• Weighing index lesion complexity versus patient characteristics to optimize DAPT benefits
Monday, June 18, 2018
5:15 PM - 6:45 PM
Rosen Shingle Creek, Sebastian K
Orlando, FL
All C3 attendees are invited to attend. Visit http://www.c3conference.net/ to register for the C3 Conference.
• Improving individualized dual antiplatelet regimens in complex patients
• Performing genetic testing to guide DAPT
• Weighing index lesion complexity versus patient characteristics to optimize DAPT benefits
Monday, June 18, 2018
5:15 PM - 6:45 PM
Rosen Shingle Creek, Sebastian K
Orlando, FL
All C3 attendees are invited to attend. Visit http://www.c3conference.net/ to register for the C3 Conference.
This activity is intended for interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, technologists, nurses, and other clinicians who manage thrombotic risks across diverse patient populations.
Upon completion of this activity, participants will be able to:
• Discuss the latest guidelines for antiplatelet therapy in ACS
• Compare and contrast the pharmacodynamic properties of antiplatelet therapies
• Outline the most recent efficacy and safety data of antiplatelet therapies and dual antiplatelet regimens for patients undergoing PCI
• Discuss the advantages and challenges of maintaining longer term antiplatelet therapy for reduction of cardiovascular risk
• Discuss the latest guidelines for antiplatelet therapy in ACS
• Compare and contrast the pharmacodynamic properties of antiplatelet therapies
• Outline the most recent efficacy and safety data of antiplatelet therapies and dual antiplatelet regimens for patients undergoing PCI
• Discuss the advantages and challenges of maintaining longer term antiplatelet therapy for reduction of cardiovascular risk
Sponsored by the Academy for Continued Healthcare Learning.
Supported by an educational grant from AstraZeneca.
Key Updates in Guidelines for Antiplatelet Therapy in ACS
Christian Ruff, MD, MPH
Pharmacologic Advantages and Challenges Among the Available Oral Antiplatelet Agents
Sandeep Nathan, MD, MSc
Impact of Presentation and Complexity of Coronary Artery Disease on Duration of DAPT Post-PCI
Marc Bonaca, MD, MPH
Should We Perform Platelet Function and Pharmacogenetic Testing to Determine the Best Antiplatelet Therapy?
Bryan Kluck, DO
Future Approaches to DAPT to Address Patient with High-risk of Bleeding
Freek Verheugt, MD, PhD
Panel Discussion: Maintaining Compliance in DAPT
All Faculty
Panel Discussion: How Do I Choose and Maintain an Antiplatelet Agent in Complex Clinical Scenarios?
All Faculty
STEMI in an Elderly Patient Who Cannot Swallow Pills
Bryan Kluck, DO
55-year-old Male with Diabetes Who Presents with Chest Pain and Positive Cardiac Biomarkers, NSTEMI
Sandeep Nathan, MD, MSc
Patient with Prior History of MI, MVD Stenting with DES Follow-up 11 Months Later
Ramesh Daggubati, MD
Christian Ruff, MD, MPH
Pharmacologic Advantages and Challenges Among the Available Oral Antiplatelet Agents
Sandeep Nathan, MD, MSc
Impact of Presentation and Complexity of Coronary Artery Disease on Duration of DAPT Post-PCI
Marc Bonaca, MD, MPH
Should We Perform Platelet Function and Pharmacogenetic Testing to Determine the Best Antiplatelet Therapy?
Bryan Kluck, DO
Future Approaches to DAPT to Address Patient with High-risk of Bleeding
Freek Verheugt, MD, PhD
Panel Discussion: Maintaining Compliance in DAPT
All Faculty
Panel Discussion: How Do I Choose and Maintain an Antiplatelet Agent in Complex Clinical Scenarios?
All Faculty
STEMI in an Elderly Patient Who Cannot Swallow Pills
Bryan Kluck, DO
55-year-old Male with Diabetes Who Presents with Chest Pain and Positive Cardiac Biomarkers, NSTEMI
Sandeep Nathan, MD, MSc
Patient with Prior History of MI, MVD Stenting with DES Follow-up 11 Months Later
Ramesh Daggubati, MD
Raj Dave, MD, FACC, FSCAI (Chair)
Chief Medical Executive, Holy Spirit Cardiovascular Institute
Chairman, Department of Cardiology
Director, Cardiac Catheterization Laboratories
Ortenzio Heart Center, Holy Spirit Hospital
Camp Hill, PA
Marc P. Bonaca, MD, MPH
Chief Medical Executive, Holy Spirit Cardiovascular Institute
Chairman, Department of Cardiology
Director, Cardiac Catheterization Laboratories
Ortenzio Heart Center, Holy Spirit Hospital
Camp Hill, PA
Bryan Kluck, DO (Co-chair)
Cardiologist
Lehigh Valley Health Network
Lehigh Valley Health Network
Allentown, PA
Freek Verheugt, MD, PhD (Co-chair)
Professor of Cardiology, Heart-Lung Centre at University Medical Centre of Nijmegen
Chairman, Department of Cardiology at Onze Lieve Vrouwe Gasthuis
The Netherlands
Marc P. Bonaca, MD, MPH
Assistant Professor, Harvard Medical School
Associate Physician, Brigham and Women’s Hospital
Boston, MA
Ramesh Daggubati, MD
Associate Chief of Cardiology
NYU Winthrop Hospital
NYU Winthrop Hospital
Mineola, NY
Sandeep Nathan, MD, MSc
Associate Professor of Medicine
Medical Director, Cardiac Intensive Care Unit
Director, Interventional Cardiology Fellowship Program
Co-Director, Cardiac Catheterization Laboratory
Heart and Vascular Center, University of Chicago Medicine
Chicago, IL
Christian T. Ruff, MD, MPH
Assistant Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women's Hospital
Boston, MA
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Interventional Academy. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
ACHL designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACHL designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
